Latest Tibotec Stories
Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities ZUG, Switzerland, Aug.
New research report “KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen” elaborated by FirstWord has been recently published by Market Publishers Ltd.
HUDDINGE, Sweden, July 6, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), is an emerging research-based specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435 has received "Fast Track" designation by the U.S.
CORK, Ireland, June 28, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTAÂ® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent. PREZISTA, co-administered with ritonavir (PREZISTA/ritonavir), and...